Find Clinical Trials

All CategoriesMedications / Interventions»Qq-Rr»Rifampin

Join Paid Clinical Trials

  • Conditions:   Idiopathic Infantile Hypercalcaemia - Severe Form;   Genetic Disease;   Hypercalcemia, Idiopathic, of Infancy;   Hypercalciuric Hypercalcemia;   Idiopathic Infantile Hypercalcemia - Mild Form;   Hypercalciuria
    Intervention:   Drug: Rifampin
    Sponsors:   Children's Hospital of Philadelphia;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  • Condition:   RSV Infection
    Interventions:   Drug: EDP-938;   Drug: Itraconazole;   Drug: Rifampin;   Drug: Quinidine
    Sponsors:   Enanta Pharmaceuticals;   Pharmaceutical Research Associates

  • Condition:   Healthy Volunteer
    Interventions:   Drug: Ozanimod;   Drug: Gemfibrozil;   Drug: Itraconazole;   Drug: Rifampin
    Sponsor:   Celgene

  • Condition:   Advanced Solid Neoplasm
    Interventions:   Drug: Pevonedistat;   Drug: Rifampin;   Drug: Docetaxel;   Drug: Carboplatin;   Drug: Paclitaxel
    Sponsor:   Millennium Pharmaceuticals, Inc.

  • Condition:   Healthy
    Interventions:   Drug: Buprenorphine;   Drug: Rifampin;   Other: grapefruit juice;   Drug: Ketoconazole
    Sponsor:   Washington University School of Medicine

  • Conditions:   Osteomyelitis;   Diabetes;   Amputation
    Interventions:   Drug: Rifampin;   Drug: Riboflavin Placebo
    Sponsor:   VA Office of Research and Development

  • Condition:   Sarcoidosis; Antimycobacterial Therapy
    Interventions:   Drug: Levofloxacin;   Drug: Ethambutol;   Drug: Azithromycin;   Drug: Rifampin;   Drug: Placebo
    Sponsors:   Vanderbilt University;   National Heart, Lung, and Blood Institute (NHLBI)

  • Conditions:   Mycobacterium Avium Complex;   Nontuberculous Mycobacterium Infection
    Interventions:   Drug: Azithromycin;   Drug: Ethambutol;   Drug: Rifampin
    Sponsors:   Kevin Winthrop;   Patient-Centered Outcomes Research Institute;   National Jewish Health;   The University of Texas Health Science Center at Tyler;   University Health Network, Toronto;   New York University;   Medical University of South Carolina;   Mayo Clinic;   Georgetown University;   University of Chicago;   Louisiana State University Health Sciences Center in New Orleans;   University of California, San Diego;   Stanford University;   University of Kansas;   Vancouver Clinic;   University of California, San Francisco;   University of Washington;   Johns Hopkins University;   University of Miami;   Emory University;   University of Iowa;   The Oregon Clinic;   University of North Carolina;   Yale University;   Weill Medical College of Cornell University;   Columbia University;   The University of Texas Health Science Center at San Antonio

  • Condition:   Osteomyelitis
    Interventions:   Drug: oral antibiotics;   Procedure: intravenous antibiotics
    Sponsors:   Julio Ramirez;   University of Louisville

  • Conditions:   Non-Small Cell Lung Cancer ALK-positive;   Non-Small Cell Lung Cancer c-Met Dependent;   Non-Small Cell Lung Cancer ROS Marker Positive;   Systemic Anaplastic Large-Cell Lymphoma;   Advanced Malignancies Except Leukemia
    Interventions:   Drug: PF-02341066;   Drug: Rifampin;   Drug: Itraconazole
    Sponsor:   Pfizer

  • Conditions:   Latent Tuberculosis;   Human Immunodeficiency Virus;   Rifamycins Causing Adverse Effects in Therapeutic Use;   Drug Interaction Potentiation
    Interventions:   Drug: Doravirine (DOR);   Drug: Rifapentine (RPT);   Drug: Isoniazid (INH)
    Sponsors:   Walter K. Kraft;   Merck Sharp & Dohme Corp.

  • Condition:   HIV Infections
    Interventions:   Drug: atazanavir/cobicistat;   Drug: darunavir/ritonavir;   Drug: darunavir/cobicistat;   Drug: etravirine;   Drug: elvitegravir/cobicistat;   Drug: dolutegravir;   Drug: tenofovir alafenamide fumarate (TAF);   Drug: TAF/cobicistat;   Drug: TAF/ritonavir;   Drug: efavirenz;   Drug: lopinavir/ritonavir;   Drug: nevirapine;   Drug: rifampicin;   Drug: ethambutol;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: kanamycin;   Drug: amikacin;   Drug: capreomycin;   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: ofloxacin;   Drug: ethionamide/prothionamide;   Drug: terizidone/cycloserine;   Drug: para-aminosalicylic acid (PAS);   Drug: high dose isoniazid (INH);   Drug: bedaquiline;   Drug: clofazamine;   Drug: delamanid;   Drug: linezolid;   Drug: pretomanid;   Drug: atazanavir/ritonavir/tenofovir;   Drug: ethinyl estradiol oral contraceptive;   Drug: etonogestrel implant
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

  • Condition:   Healthy Volunteers
    Interventions:   Drug: Vemlidy (tenofivir alafenamide);   Drug: Priftin (rifapentine);   Drug: Isoniazid;   Dietary Supplement: Pyridoxine
    Sponsor:   National Institutes of Health Clinical Center (CC)

Login to Get Started